Literature DB >> 26629271

Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes.

Loretta Fala.   

Abstract

Entities:  

Year:  2015        PMID： 26629271      PMCID： PMC4665046     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  9 in total

Review 1.  The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

Authors:  R A DeFronzo; J A Davidson; S Del Prato
Journal:  Diabetes Obes Metab       Date:  2012-01       Impact factor: 6.577

2.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

3.  AACE comprehensive diabetes management algorithm 2013.

Authors:  Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Michael B Davidson; Daniel Einhorn; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo Umpierrez; Michael H Davidson
Journal:  Endocr Pract       Date:  2013 Mar-Apr       Impact factor: 3.443

4.  Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence.

Authors:  James P Boyle; Theodore J Thompson; Edward W Gregg; Lawrence E Barker; David F Williamson
Journal:  Popul Health Metr       Date:  2010-10-22

5.  Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.

Authors:  Hans-Ulrich Häring; Ludwig Merker; Elke Seewaldt-Becker; Marc Weimer; Thomas Meinicke; Uli C Broedl; Hans J Woerle
Journal:  Diabetes Care       Date:  2014-04-10       Impact factor: 19.112

6.  Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Michael Roden; Jianping Weng; Jens Eilbracht; Bruno Delafont; Gabriel Kim; Hans J Woerle; Uli C Broedl
Journal:  Lancet Diabetes Endocrinol       Date:  2013-09-09       Impact factor: 32.069

Review 7.  Understanding the kidneys' role in blood glucose regulation.

Authors:  Curtis L Triplitt
Journal:  Am J Manag Care       Date:  2012-01       Impact factor: 2.229

8.  Executive summary: Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

9.  Economic costs of diabetes in the U.S. in 2012.

Authors: 
Journal:  Diabetes Care       Date:  2013-03-06       Impact factor: 19.112
  9 in total
  5 in total

Review 1.  Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.

Authors:  Abdullah Kaplan; Emna Abidi; Ahmed El-Yazbi; Ali Eid; George W Booz; Fouad A Zouein
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

Review 2.  Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Manuel Otero-Santiago; Laura Anido-Varela; Sandra Moraña-Fernández; Estefanía Tarazón; Esther Roselló-Lletí; Manuel Portolés; Oreste Gualillo; José Ramón González-Juanatey; Francisca Lago
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

3.  The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.

Authors:  Sebastian Steven; Matthias Oelze; Alina Hanf; Swenja Kröller-Schön; Fatemeh Kashani; Siyer Roohani; Philipp Welschof; Maximilian Kopp; Ute Gödtel-Armbrust; Ning Xia; Huige Li; Eberhard Schulz; Karl J Lackner; Leszek Wojnowski; Serge P Bottari; Philip Wenzel; Eric Mayoux; Thomas Münzel; Andreas Daiber
Journal:  Redox Biol       Date:  2017-06-22       Impact factor: 11.799

Review 4.  Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy.

Authors:  Viswanathan Mohan; Ambrish Mithal; Shashank R Joshi; S R Aravind; Subhankar Chowdhury
Journal:  Drug Des Devel Ther       Date:  2020-06-24       Impact factor: 4.162

5.  Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study.

Authors:  Fahad M Althobaiti; Safaa M Alsanosi; Alaa H Falemban; Abdullah R Alzahrani; Salma A Fataha; Sara O Salih; Ali M Alrumaih; Khalid N Alotaibi; Hazim M Althobaiti; Saeed S Al-Ghamdi; Nahla Ayoub
Journal:  J Clin Med       Date:  2022-08-16       Impact factor: 4.964
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.